Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services Hollis-Eden Pharmaceuticals, Inc. today announced that it was informed late Wednesday, ...

NEW YORK (MarketWatch) -- Hollis-Eden Pharmaceuticals shares tumbled almost 30% in premarket trade Thursday after it said the Department of Health has found its Neumune drug for the treatment of Acute ...

In a non-human primate study, high doses of Neumune resulted in 90 percent survival against a lethal level of radiation. It's not much of a plan, especially considering that potassium iodide only ...

March 16 (Reuters) - Hollis-Eden Pharmaceuticals Inc. said on Friday it will curtail further development of its radiation drug Neumune after the U.S. Department of Health and Human Services (HHS) ...

Since the United States first tested atomic bombs and then dropped two on Japan to end World War II, the nation has spent trillions of dollars on its nuclear arsenal. Over that half century very ...

SAN DIEGO, Nov. 3 (UPI) -- Hollis-Eden Pharmaceuticals said Friday there are likely no competing bids on a plum U.S. government contract for an anti-radiation drug. The company said it has received a ...

WASHINGTON, May 12 (UPI) -- Hollis-Eden reported a net loss of $6.9 million in first quarter earnings and analysts think the company will have to win a federal contract for its acute radiation ...

BANGALORE, March 16 (Reuters) - Shares of Hollis-Eden Pharmaceuticals Inc. rose as much as 52 percent after the company said it is stopping further development of radiation drug Neumune and instead ...

There's been a scientific breakthrough in the war on terrorism. Hollis-Eden Pharmaceuticals based in San Diego, California, has created what could be the antidote to a radiation attack. The hormone ...